RenovoRx, Inc.

Healthcare · Biotechnology · United States

Last price 1.49 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 67.24M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.